Moderna 10-Q: Q3 Swing to $162M Profit on $1.3B Revenue, $8.0B Cash
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna swung to a $162 million Q3 profit ($0.38 diluted EPS) on $1.3 billion of revenue, up 29%, with $8.0 billion of cash and investments after issuing $3.0 billion of convertible notes.
Key Events · Earnings and Guidance · MRNA
-
Q3 Swing to $162M Profit
Net income of $162 million ($0.38 diluted EPS) versus a $200 million loss ($0.51) in Q3 2025, on total revenue of $1,313 million, up 29% from $1,016 million.
-
COVID Sales Drive Revenue
COVID vaccine sales accounted for $1,244 million of the $1,273 million in net product sales; U.S. sales were roughly flat at $771 million, while Europe jumped to $314 million from $16 million on government deliveries.
-
R&D Cut 27% to $583M
Research and development fell $218 million year over year on lower late-stage trial spending and personnel costs; nine-month R&D was $1,883 million, down 20%.
-
Cash of $8.0B After Convertible Issue
Cash, cash equivalents and investments totaled $7,976 million at September 30, 2026, down $159 million from year-end despite $2.7 billion of operating cash burn, after $3.0 billion of 0.00% convertible notes due 2032 and $329 million of capped calls.
Analysis · MRNA · Life Sciences
The headline is Moderna's first quarterly profit in years: $162 million of net income ($0.38 diluted EPS) on $1.3 billion of revenue, up 29%, versus a $200 million loss a year earlier. Driving the swing were a 27% cut in R&D to $583 million and $1.24 billion of COVID vaccine sales, mostly international government deliveries, while U.S. product sales were flat. After the $3.0 billion zero-coupon convertible notes issued September 1, 2026 and the $329 million capped call purchase, the balance sheet still carries $7,976 million of cash and investments; nine-month operating cash burn was $2.7 billion. Management says resources fund operations for at least the next 12 months. Because the convertible notes convert at $210.58, below today's $255.50 price, the 14 million underlying shares are in the money and dilution is real if holders convert, though the capped calls offset it up to $392.62.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRNA was trading at $255.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.5B. The 52-week trading range was $22.28 to $267.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.